公开(公告)号：US20240117190A1

公开(公告)日：2024-04-11

申请号：US18237113

申请日：2023-08-23

申请人： THE JAPAN STEEL WORKS, LTD.

发明人： Keisuke WASHIO ,  Ryo YAMAWAKI

IPC分类号： C09B57/00 ,  C07F9/11 ,  C07F9/12 ,  C07F9/30 ,  C07F9/38 ,  C08K5/523 ,  C08K5/5357

CPC分类号： C09B57/00 ,  C07F9/11 ,  C07F9/12 ,  C07F9/304 ,  C07F9/3808 ,  C07F9/3882 ,  C07F9/3891 ,  C08K5/523 ,  C08K5/5357 ,  G02B5/208

摘要： Provided is a light absorbing agent that excels in miscibility with a resin, a method of manufacturing such a light absorbing agent, a composition that excels in dispersiveness of such a light absorbing agent, and an optical member that excels in visible light transmitting performance and near-infrared radiation blocking performance. The light absorbing agent contains a compound expressed by Formula (1) below and a copper ion.




In the above, R1 is a group expressed by Formula (2) above, R10 is an alkylene group or arylene group that may have a substituent, R12 is an alkylene group or arylene group that may have a substituent, and the other symbols are as described in the specification.

公开(公告)号：US20240109924A1

公开(公告)日：2024-04-04

申请号：US18274805

申请日：2022-01-31

申请人： SANIFIT THERAPEUTICS, S.A.

发明人： María del Mar PÉREZ FERRER ,  Miquel David FERRER REYNÉS ,  Mohamad Firas BASSISSI ,  Carolina SALCEDO ROCA ,  Carme SERRA COMAS ,  Juan Lorenzo CATENA RUIZ ,  Amadeu LLEBARIA SOLDEVILA ,  Joaquín ORTEGA CASTRO ,  Joan PERELLÓ BESTARD

IPC分类号： C07F9/09 ,  A61P7/08 ,  A61P39/00 ,  C07F9/11 ,  C07F9/6503 ,  C07F9/6509 ,  C07F9/6518 ,  C07F9/6553

CPC分类号： C07F9/093 ,  A61P7/08 ,  A61P39/00 ,  C07F9/11 ,  C07F9/65031 ,  C07F9/650952 ,  C07F9/6518 ,  C07F9/655345

摘要： The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R1, R3, R7, and R11 are OPO32−, and R5 and R9 are selected from the group consisting of —O(Alkyl)nX, —O(Alkyl)yCy(Alkyl2)y-Z, —O(Alkyl)yA(Alkyl)y-Z′, and their thiophosphate analogs. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.

公开(公告)号：US11136342B2

公开(公告)日：2021-10-05

申请号：US16459430

申请日：2019-07-01

申请人： Acorda Therapeutics, Inc.

发明人： Naweed Muhammad ,  Keith R. Bley

IPC分类号： C07F9/09 ,  A61K31/661 ,  A61K47/54 ,  C07C233/25 ,  C07F9/11

摘要： The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

公开(公告)号：US10941095B2

公开(公告)日：2021-03-09

申请号：US16142547

申请日：2018-09-26

申请人： Esperion Therapeutics, Inc.

发明人： Jean-Louis H. Dasseux ,  Carmen D. Oniciu

IPC分类号： C07C31/27 ,  C07C61/12 ,  C07C47/34 ,  C07C309/25 ,  C07F9/24 ,  C07D261/12 ,  C07C59/105 ,  C07C33/26 ,  C07C47/19 ,  C07C69/675 ,  C07C69/003 ,  C07C69/017 ,  C07C309/08 ,  C07F9/11 ,  C07C309/24 ,  C07F9/12 ,  C07D495/04 ,  C07C255/00 ,  C07D257/04 ,  C07D261/08 ,  C07D305/12 ,  C07D307/33 ,  C07C59/01 ,  C07D309/30 ,  A61K31/194 ,  A61K31/23 ,  A61K31/20 ,  A61K31/191 ,  C07C31/20 ,  C07C31/22 ,  C07C31/24 ,  C07C59/11 ,  C07C59/285 ,  C07C59/29 ,  C07C59/46 ,  C07C59/48 ,  C07C59/54 ,  C07C62/06 ,  C07C65/17 ,  C07C69/757 ,  C07D213/80 ,  C07D309/10 ,  C07D309/12 ,  C07D405/12 ,  C07F9/09 ,  C07F9/117 ,  C07F9/44 ,  C07C59/245 ,  C07C62/02

摘要： The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

公开(公告)号：US20200157126A1

公开(公告)日：2020-05-21

申请号：US16459430

申请日：2019-07-01

申请人： Acorda Therapeutics, Inc.

发明人： Naweed MUHAMMAD ,  Keith R. BLEY

IPC分类号： C07F9/09 ,  A61K31/661 ,  A61K47/54 ,  C07C233/25 ,  C07F9/11

摘要： The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

公开(公告)号：US10439143B2

公开(公告)日：2019-10-08

申请号：US15739837

申请日：2016-07-22

申请人： Nippon Chemical Industrial Co., Ltd.

发明人： Fumihiro Yonekawa ,  Yohei Mizuguchi

IPC分类号： H01L51/00 ,  C07F9/54 ,  C07F5/02 ,  C07F9/11 ,  C08K5/10 ,  C08K5/19 ,  C08K5/3445 ,  C08K5/42 ,  C08K5/49 ,  C08K5/521 ,  C08L65/00 ,  H01L51/50 ,  C07C69/78 ,  C07C69/80 ,  C07C69/96 ,  C07C309/73 ,  C07D317/36 ,  C09K11/06

摘要： An additive for a light-emitting layer contains a compound represented by formula (1): where X is P, C, or S; A is a cyclic hydrocarbon group that may have H, a direct bond, a chain hydrocarbon group, or a heteroatom; R is H or an alkyl group, and a plurality of R may link together to form a ring, and if said ring is formed, at least one R is an alkyl group; m is 0 or 1; r is 1 when X is a phosphorous atom or a carbon atom and 2 when X is a sulfur atom; n is a number represented by 3-m when X is a phosphorous atom, and a number represented by 2-m if X is a carbon atom or a sulfur atom; and p is 1 when m is 0, at least 1 when m is 1, and is a substitutable number in A.

公开(公告)号：US20190184014A1

公开(公告)日：2019-06-20

申请号：US16285358

申请日：2019-02-26

申请人： Wisconsin Alumni Research Foundation

发明人： Jamey Weichert ,  Anatoly Pinchuk ,  Wolfgang Axel Tome

IPC分类号： A61K41/00 ,  A61N5/10 ,  A61K49/08 ,  A61K49/10 ,  C07F9/11 ,  C07F9/09 ,  C07F9/6561 ,  C07F9/6524 ,  C07F9/6515 ,  G01N33/60 ,  A61K51/04 ,  C07F9/10 ,  G01N33/58 ,  G01N33/574

摘要： Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

公开(公告)号：US10308671B2

公开(公告)日：2019-06-04

申请号：US16062258

申请日：2016-12-14

申请人： Max-Planck-Gesellschaft zur Förderung ,  Armin Giese ,  Felix Schmidt

发明人： Armin Giese ,  Felix Schmidt ,  Christian Griesinger ,  Andrei Leonov ,  Sergey Ryazanov

IPC分类号： C07F9/11 ,  A61P25/28 ,  A61P25/16

摘要： The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.

公开(公告)号：US10265398B2

公开(公告)日：2019-04-23

申请号：US15343580

申请日：2016-11-04

申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION

发明人： Jamey Weichert ,  Anatoly Pinchuk ,  Wolfgang Axel Tomé

IPC分类号： A61K49/00 ,  A61K51/04 ,  G01N33/58 ,  C07F9/10 ,  A61K41/00 ,  A61K49/08 ,  A61K49/10 ,  G01N33/574 ,  A61N5/10 ,  G01N33/60 ,  C07F9/6515 ,  C07F9/6524 ,  C07F9/6561 ,  C07F9/09 ,  C07F9/11 ,  A61K39/00

摘要： Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

公开(公告)号：US10246341B2

公开(公告)日：2019-04-02

申请号：US15789997

申请日：2017-10-21

申请人： XIANGTAN UNIVERSITY

发明人： Lixin Yang ,  Mi Fu ,  Yi Wang ,  Hongyu Qi ,  Yu Xu ,  Yali Liu ,  Yalin Gui ,  Jing He

IPC分类号： C01D15/00 ,  C01D15/08 ,  B01D11/04 ,  B01D12/00 ,  C07F9/11 ,  C01F5/22 ,  C01F5/24 ,  C07B63/00

摘要： The present invention discloses a method for producing lithium carbonate from a low-lithium brine by separating magnesium and enriching lithium. A salt-lake brine is used as a raw material and is converted into halide salts through dehydration by evaporation and separation by crystallization; the halide salts are directly extracted using trialkyl phosphate or a mixture of trialkyl phosphate and monohydric alcohol, and an organic extraction phase as well as remaining halide salts are obtained after solid-liquid separation; reverse extraction is performed on the organic extraction phase to obtain a lithium-rich solution with a low magnesium-to-lithium ratio, and lithium carbonate is obtained after concentration and removal of magnesium by alkalization. The used solid-liquid extraction method is simple with no co-extraction agent used, and a solute distribution driving force is strong, unaffected by phase equilibrium of the brine extraction agent. The mass ratio of magnesium-to-lithium significantly decreases in the extraction phase.